A task group of the Science Committee of the Association for Palliative Medicine of Great
Britain and Ireland (APM) was convened to produce some up-to-date, evidence-based …

Despite the increasing clinical use of transdermal buprenorphine, questions have persisted
about the possibility of a ceiling effect for analgesia, its combination with other μ‐opioid …

This paper is the 28th consecutive installment of the annual review of research concerning
the endogenous opioid system, now spanning over a quarter-century of research. It …

Background This review is an update of a previously published review in the Cochrane
Database of Systematic Reviews (Issue 1, 2006). Breakthrough pain is a transient …

The management of breakthrough pain (BTP) should be handled as a separate and distinct
aspect of each patient's pain syndrome. This approach allows the clinician to consider BTP …

According to new preclinical data, treatment of bone cancer pain requires multidisciplinary
therapies such as radiotherapy applied to the painful area along with systemic treatment …

Breakthrough cancer pain (BTcP) has been defined as a transitory increase in pain intensity
on a baseline pain of moderate intensity in patients on analgesic treatment regularly …

The use of supplemental doses of opioids is commonly suggested to manage breakthrough
pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl …

Introduction Chronic pain and breakthrough cancer pain (BTcP) have a high prevalence in
all cancer types and cancer stages, combined with a significant physical, psychological, and …

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough
pain in cancer patients. The intravenous route has been proven to be safe and effective …